News Release

Bone-grafting biomaterial that selectively destroys bone cancer cells and bacteria

Peer-Reviewed Publication

KeAi Communications Co., Ltd.

Figure 1. Graphical abstract summarising study methodology and its main findings.

image: 

Figure 1. Graphical abstract summarising study methodology and its main findings. Gallium-containing bioactive glasses (Ga-BGs) were produced by the melt-quenching technique and characterised by MAS-NMR and RAMAN spectroscopy. Ga-BGs ion leaching profiles were verified by ICP-OES (1). Therapeutic windows for gallium were determined by treating healthy and osteosarcoma cell lines with gallium nitrate (2). Ga-BGs were shown to selectively kill osteosarcoma cells and prevent growth of P.aeruginosa (3). High-throughput RNA sequencing revealed that excessive Ga3+ influx in cancer cells promotes iron metabolism disruption leading to excessive oxidative stress, activating self-destructing intracellular pathways. Gallium was also shown to inhibit pro-oncogenic genes (4).

view more 

Credit: Dr Lucas Souza

Primary bone tumors, such as osteosarcoma, have seen stagnant survival rates over the past four decades. Surgical removal of the tumor is critical, but local recurrence may occur when tumours are close to vital structures, often resulting in amputation. Furthermore, these surgeries are associated with significant bone loss and implant failure due to infection.

An international team of researchers led by the Royal Orthopaedic Hospital NHS Foundation Trust, Aston University, and the Brazilian Aeronautics Institute of Technology, has developed an advanced synthetic grafting material. By incorporating gallium oxide into the traditional "Bioglass 45S5" matrix, they created a multi-functional material that simultaneously eradicates residual cancer cells, prevents bacterial colonisation, and regenerates missing bone tissue.

"Our multi-functional biomaterial acts as a localised drug delivery system (Figure 1.1), offering a therapeutic strategy to selectively destroy residual tumour cells where the surgery took place, while providing calcium, phosphate, and silicon ions needed to grow back healthy bone," explains Dr Lucas Souza, the study's principal investigator from the Royal Orthopaedic Hospital NHS Foundation Trust (Figure 1.2).

"This development leads us into new frontiers of both therapeutics and prophylaxis against the most devasting complications of limb-salvage surgery, specifically local recurrence and infection, which threaten limbs and compromise patient survival" says co-author Jonathan Stevenson, Consultant Orthopaedic oncology surgeon at the Royal Orthopaedic Hospital.

Through high-throughput RNA sequencing, the team uncovered a highly selective molecular mechanism. "Because bone cancer cells overexpress transferrin receptors to fuel their rapid growth, they absorb four to eight times more gallium than healthy cells," says Souza. "Once inside the malignant cells, gallium mimics iron but cannot participate in essential redox reactions. This causes immediate iron depletion, overwhelming oxidative stress, and a catastrophic cellular crisis that forces the cancer cells down apoptotic and ferroptotic self-destruction pathways (Figure 1.4)."

In contrast, healthy bone cells easily manage the temporary stress via natural antioxidant mechanisms and fully recover within days.

Beyond its potent anti-cancer properties, the material also aids in preventing surgical site infection. "The optimal 5% gallium glass formulation completely inhibited the growth of the aggressive, gram-negative pathogen Pseudomonas aeruginosa," shares Stevenson (Figure 1.3). "This dual therapeutic action effectively seals off the surgical site from deadly hospital-acquired infections while the glass degrades to make space for brand new bone."

###

Contact the author: Dr Lucas Souza, Royal Orthopaedic Hospital NHS Foundation Trust, lucas.souza@nhs.net.

The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 200 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.